TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal STRING Test With Oral Immunotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria: • Participants, aged 5-55 years enrolled in the parent COMBINE trial~* Able to swallow the EST.~Exclusion Criteria: • Allergy to, or inability to ingest, gelatin~-

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- String Test-cohort A (Type: OTHER): Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~A. Omalizumab for 8 weeks followed by mOIT with placebo for dupilumab for 24 weeks (Cohort A: Omalizumab-facilitated mOIT)
- String Test-cohort B (Type: OTHER): Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~B. Omalizumab for 8 weeks followed by mOIT with dupilumab for 24 weeks (Cohort B: Omalizumab-facilitated mOIT with concurrent dupilumab)
- String Test-cohort C (Type: OTHER): Participants in the COMBINE study will have an EST performed at pre- specified timepoints (screening, week 8, and week 32) and as needed depending on GI symptoms.~C. Placebo for omalizumab for 8 weeks followed by mOIT with dupilumab for 24 weeks (Cohort C: mOIT with concurrent dupilumab)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Platelet Function With New Pediatric Oxygenator and Heparin and Non Heparin Coating in Pediatric Cardiac Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Infants/children (weighting less than 18 Kg) undergoing surgical repair of congenital heart defects on CPB, presenting a saturation \> 85% preoperatively.~Exclusion Criteria:~* Newborns, infants/children with Down syndrome, other syndromes or chromosomal abnormalities prematurity,~* use of circulatory arrest,~* expected perfusion time \< 1 hour, documented coagulation disorders, use of anticoagulant or antiplatelet drugs within 48 hours of surgery, previous heart surgery and procedures requiring a return on CPB (2 or more CPB runs),~* cyanosis defined as oxygen saturation lower than 85%.

- Gender: ALL
- Minimum Age: 30 Days
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Balance Circuit (Type: OTHER): 24 patients will be assigned to the Balance group , using a non -heparin extracorporeal pediatric device for operation . The intervention is to use the Balance circuit for this arm
- Carmeda Circuit (Type: OTHER): 24 patients will be assigned to the Carmeda group, using a coated heparin extracorporeal pediatric device for operation.~The intervention is to use the Carmeda circuit for this arm. The intervention is the Carmeda circuit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Stress Inoculation Training in Medical Education

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* 1st and 2nd year medical students who are at least 18 years old~Exclusion Criteria:~* Prior airway management experience (including but not limited to former medics, respiratory technicians, CRNAs)~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Lecture (Type: NO_INTERVENTION): an initial brief lecture with no further training
- Stress management (Type: EXPERIMENTAL): an initial brief lecture with stress management lecture
- Hands-on training (Type: ACTIVE_COMPARATOR): an initial brief lecture with addition hands-on training for the task
- Stress management and hands-on training (Type: EXPERIMENTAL): an initial brief lecture with both stress management lecture and additional hands-on training

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endovascular Magnesium Sampling in Acute Stroke

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient with acute cerebral ischemia due to ICA or MCA occlusion,~2. Patient already enrolled in the NIH FAST-MAG clinical trial,~3. Patient's clinical attending physician plans mechanical embolectomy procedure as part of routine clinical care.~4. Age 40-95 inclusive (age criteria for FAST-MAG Trial).~Exclusion Criteria:~1. Technical inability to navigate microcatheter to target clot.~2. Patient or surrogate unavailable for consent

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Endovascular Sampling (Type: EXPERIMENTAL): Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations in acute stroke patients undergoing endovascular recanalization who received intravenous Magnesium Sulfate as a part of the FAST-MAG study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Cue Exposure Training for Overweight Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Being a patient in the Maastricht University Medical Center COACH unit for obese children and adolescents.~* Overweight, according to the sex and age specific cut-off point for overweight in children, as defined by Cole and colleagues (2000).~* Age: 12 - 18 years~Exclusion Criteria:~* Not being overweight (anymore, due to weight loss)~* Not able to speak and/or write Dutch

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Food cue exposure (Type: EXPERIMENTAL): None
- Psycho-education (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Long-term Effectiveness of Zomacton® and Treatment Adherence in Patients With Growth Hormone Deficiency or Ullrich-Turner Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Pediatric patients (\< 18 years) with growth hormone deficiency or growth retardation due to Ullrich-Turner-Syndrome~* Patients already receiving or who have been prescribed Zomacton® de novo according to its German label; the decision to prescribe Zomacton® was made independently from participation and prior to enrollment in this study.~* Patient and their parents (or legal representatives) who are willing and able to provide signed informed consent for use of their personal data.~Exclusion Criteria:~* Participation in an interventional clinical study within the last 30 days prior to baseline visit or during the follow-up period

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Zomacton (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Role of Hyperoxia in Acute Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of signed and dated informed consent form from patient or legal authorized representative (LAR)~2. Subject or LAR stated willingness to comply with all study procedures and availability for the duration of the study~3. Males and females (of unlikely childbearing capacity) aged over 18 years.~4. Exhibiting signs and physical examination findings suggestive of an acute ischemic infarction (either a or b)~   1. A target mismatch profile of CT-perfusion or MRI determined by RAPID automated software to have a ratio of PWITmax\>6 lesion volume/DWI lesion volume \>1.2 and an NIHSS \>/=1~  2. A RAPID automated software calculated non-contrast CT-head ASPECT score of 10 and LKW ≤12 hours (in patients with symptoms discovered upon waking, the LKW is defined at the midpoint between going to sleep and awakening based on previous studies that suggest most strokes during sleep occur close to awakening)~5. Normoxic; a pulse oximetry of 94% or greater at time of screening without the use of supplemental oxygen~Exclusion Criteria:~1. Current use of supplemental oxygen~2. Prisoner~3. Documented blood glucose \<70mg/dL~4. Concurrent treatment with another investigational drug or other intervention~5. Documented history of any of the following chronic respiratory illness that require pulmonary vasodilators or supplemental oxygen at baseline: Chronic Obstructive Pulmonary Disorder (COPD), Emphysema, Interstitial Lung Disease, Restrictive Lung Disease, Pulmonary Hypertension~6. Documented history of any of the following autoimmune diseases: systemic lupus erythematosus, rheumatoid arthritis, scleroderma, primary biliary cholangitis, multiple sclerosis, inflammatory bowel disease~7. Currently being treated for an acute myocardial infarction and/or decompensated heart failure at the onset of initial ED presentation as reported by the ED provider~8. Plans for treatment with either IV tPA (alteplase) or endovascular therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperoxia (Type: EXPERIMENTAL): Will receive 15liters per minute supplemental oxygen via a partial non-rebreather facemask.
- Placebo (Type: PLACEBO_COMPARATOR): will receive 15liters per minute medical air via a partial non-rebreather facemask.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: HD Melphalan and SCT in Patients With IGDD or LCDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~DISEASE CHARACTERISTICS:~* Histologically confirmed light-chain deposition disease based on the following criteria:~  * Deposition of granular material containing free light-chain (FLC) immunoglobulins that did not bind Congo red~ * Evidence of a plasma cell dyscrasia, as defined by any of the following:~    * Monoclonal gammopathy in the serum or urine by immunofixation electrophoresis~   * Clonal plasmacytosis on bone marrow biopsy by immuno-histochemical~   * Elevated serum levels of FLC~* Patients may enroll after stem cell collection (SCC) if all prestudy requirements are completed prior to starting SCC (i.e., ≥ 2.5 x 10\^6 cells available for transplantation)~PRIOR CONCURRENT THERAPY:~* Prior chemotherapy with alkylating agent allowed provided there is no evidence of myelodysplastic syndromes~* Prior total dose of melphalan \< 300 mg~* More than 4 weeks since prior cytotoxic therapy and recovered~PATIENT CHARACTERISTICS:~* Performance status 0-2~* Left Ventricular Ejection Fraction (LVEF) ≥ 45% within the past 90 days~* diffusing capacity of lung for carbon monoxide (DLCO) ≥ 50%~Exclusion Criteria:~* No overt multiple myeloma, as defined by any of the following:~  * Greater than 30% bone marrow plasmacytosis~ * Extensive (i.e., \> 2) lytic lesions~ * Hypercalcemia~* No myocardial infarction, congestive heart failure, or arrhythmia refractory to therapy within the past 6 months~* No prior malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer from which the patient is currently in complete response, or any other cancer from which the patient has been disease-free for the past 5 years~* No HIV positivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- SCT with melphalan conditioning (Type: EXPERIMENTAL): Mobilization with Filgrastim Stem Cell Transplant Melphalan Conditioning Stem Cell infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Effectiveness of Dyadic Prolonged Exposure on 2-4 Years Old vs. Toddler-parent Focused Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Hebrew speaking toddlers with PTSD related to traumatic experience that occured at least 1 month prior to the study enrollment~2. Toddlers whose parents are living together~Exclusion Criteria:~1. Toddlers which are still dealing with an active life threatening illness and are hence going through medical procedures.~2. Toddlers with intelectual developmental disorder~3. Toddlers with an active psychosis~4. Toddlers with blindness or deafness~5. Toddlers who are currently taking psychotropic medication~6. Toddlers and parents that receive psycotherapy outside of the study for their PTSD symptoms~7. Toddlers diagnozed with autism spectrum disorder~8. Toddlers who were exposed to domestic or sexual violence

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 66 Months
- Healthy Volunteers: f

Study Arms:
- Prolonged exposure (Type: EXPERIMENTAL): See intervention description
- Child-parent Play Therapy (Type: ACTIVE_COMPARATOR): see intervention description

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prophylactic Phenobarbital After Neonatal Seizures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Birth at \> 34 weeks' gestation~* Neonatal seizures (clinical, electrographic or both), with onset in the first 120 hours after birth and resolution within 7 days of onset~* Parental informed consent~Exclusion Criteria:~* Birth at \< 34 weeks' gestation~* If the attending neonatologist attributes the seizures solely to a transient abnormality, easily correctable and unlikely to recur (eg, transient electrolyte abnormalities). If the attending neonatologist cannot be contacted, the site PI will be asked to review the available information and judge whether the infant is eligible.~* If the infant has been diagnosed with or there is a strong suspicion of an inborn error of metabolism, significant brain malformation, microcephaly (\< 3 %ile), or a chromosomal abnormality which, in the absence of seizures, is known to be independently associated with an increased likelihood of cognitive impairment~* If the infant has been diagnosed with an intrauterine viral infection~* If the infant is not expected to survive to discharge

- Gender: ALL
- Minimum Age: 2 Days
- Maximum Age: 2 Weeks
- Healthy Volunteers: f

Study Arms:
- Phenobarbital (Type: ACTIVE_COMPARATOR): Phenobarbital, 4-5 mg/kg/day, for 4 months
- Placebo (Type: PLACEBO_COMPARATOR): Placebo in a volume equivalent to active drug for 4 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* - Confirmed consensus on the diagnosis pyoderma gangrenosum by referring specialist, principal and coordinating investigator (dermatologist, clinical immunologist or rheumatologist based on PARACELSUS and Delphi score).~* Unsatisfactory response after six weeks of combined standard wound care and systemic prednisone and/or other anti-inflammatory therapy.~* Fit for hyperbaric oxygen therapy as assessed by the hyperbaric physician.~* Age ≥18 years at baseline~* All genders~* Able and willing to give written informed consent and to comply with the study requirements.~Exclusion Criteria:~* - Language barrier~* Unable to give informed consent or to comply with the trial protocol~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Hyperbaric Oxygen Therapy (Type: ACTIVE_COMPARATOR): Hyperbaric treatment will consist of 30 daily treatments in the first 6 weeks of the study, except during the weekends. After compression for 10 minutes patients will receive 80 minutes (4 times 20 minutes) 100% O2 with 3 airbrakes (21% O2) of 5 minutes at 2.4-2.5 ATA, and then 10 minutes decompression with the first part of decompression till 0.3 ATA with 100% oxygen (this will usually take seven minutes). The last 0.3 ATA will be decompressed with air. In total one hyperbaric session will be 110 minutes. Treatment will start directly at the beginning of the study.
- Control group (Type: ACTIVE_COMPARATOR): In order to compare efficacy, patients that do not wish to undergo hyperbaric treatment, will serve as a control group. At baseline they will be asked for the reason they do not wish to undergo hyperbaric treatment. All patients and controls will be asked to report pain scores using a numeric pain rating scale (NRS) and quality of life (Wound-Q) questionnaires. They will continue to receive standard care as deemed necessary by their primary physician.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ketamine Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages ≥ 18 years.~* Able to speak and understand English.~* RSE requiring IV pain medication for NRS pain score \> 5.~* No allergy to ketamine or fentanyl.~* Ability to provide informed consent.~* ≤ 24 hours from envenomation.~Exclusion Criteria:~* Pregnant or lactating.~* Prisoners.~* Refugees.~* History of schizophrenia.~* Clinically intoxicated.~* On buprenorphine therapy.~* History of uncontrolled hypertension~* Increased intracranial pressure~* Systemic envenomation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Fentanyl (Type: ACTIVE_COMPARATOR): Drug administration: A single dose of fentanyl 1mcg/kg IV, maximum 100 mcg, over 15 minutes.~Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes~* Record vital signs (HR, B/P, resp rate, O2 sat)~* Obtain and assess pain response scores~  1. Pain Numerical Rating Score (NRS - 0-10)~ 2. Richmond Agitation Sedation Scale (RASS)~ 3. Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)~* Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust~* Record any rescue meds, dose and time (Rescue medication - Fentanyl):~* 1 mcg/kg IV fentanyl (0.5 mcg/kg if age \>55 yrs)~* Defined as rescue if given \<30 min post study intervention for pain score \>5 or patient requesting additional medication.~* Patient pain satisfaction score at discharge
- Ketamine (Type: EXPERIMENTAL): Drug administration: A single dose of ketamine 0.3 mg/kg IV over 15 minutes. Time drug given will be documented Data obtained prior to med administration and then following medication administration at intervals of 15, 30, 60 and 120 minutes~* Record vital signs (HR, B/P, resp rate, O2 sat)~* Obtain and assess pain response scores~  1. Pain Numerical Rating Score (NRS - 0-10)~ 2. Richmond Agitation Sedation Scale (RASS)~ 3. Side Effect Rating Scale for Dissociative Anesthesia (SERSDA)~* Record any airway interventions required? If yes what? new supplemental O2/BVM/intubation, jaw thrust~* Record any rescue meds, dose and time (Rescue medication - Fentanyl):~* 1 mcg/kg IV fentanyl (0.5 mcg/kg if age \>55 yrs)~* Defined as rescue if given \<30 min post study intervention for pain score \>5 or patient requesting additional medication.~* Patient pain satisfaction score at discharge

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy